DIFFERENT COURSES OF HBV INFECTION AFTER LIVER TRANSPLANTATION
https://doi.org/10.15825/1995-1191-2011-2-37-45
Abstract
To compare clinical and virologic course of de novo and recurrent HBV infection 104 liver graft recipients with 6 months and more follow-up after cadaveric transplantation have been analyzed. Recurred HBV infection occurred in 7 (30.4%) out of 23 HBsAg-positive and de novo HBV infection – in 11 out of 81 (13.6%) HBsAg- negative recipients. HBeAg and IgM anti-HBc appeared in 8 recipients with de novo and in one case – with recurrent infection. Two recipients with de novo HBV developed acute hepatitis with jaundice and one – chronic hepatitis with graft cirrhosis. Only one recipient with recurrent HBV developed severe acute hepatitis HBV/ HDV, with anti-HBs seroconversion after 12 weeks of peginterferon alfa treatment. Nucleoside analogs (NA) were started in all 11 de novo HBV cases and in 5 cases of recurrent HBV infection. Treatment with NA effec- tively suppressed HBV DNA replication in both recurrent and de novo infections; HBsAg clearance occurred in 64% of de novo HBV and in 20% – of recurrent HBV cases. No secondary drug resistance occurred. De novo HBV infection is a self-limited disease in most cases, and preemptive NA treatment is the best treatment choice. Recurrent HBV infection is usually chronic, and pegylated interferon may be under consideration as well as NA.
About the Authors
V. E. Syutkin
N.V. Sklifosovsky Institute research of Emergency Medicine, Moscow
Russian Federation
Russian Federation
O. I. Andreytzeva
N.V. Sklifosovsky Institute research of Emergency Medicine, Moscow
Russian Federation
Russian Federation
A. A. Salienko
N.V. Sklifosovsky Institute research of Emergency Medicine, Moscow
Russian Federation
Russian Federation
A. O. Chugunov
N.V. Sklifosovsky Institute research of Emergency Medicine, Moscow
Russian Federation
Russian Federation
A. V. Chzhao
N.V. Sklifosovsky Institute research of Emergency Medicine, Moscow
Russian Federation
Russian Federation
References
1. Сюткин В.Е., Андрейцева О.И., Салиенко А.А. и др. Вакцинация против HBV больных, находящихся в листе ожидания трансплантации печени // Инфекци- онные болезни. 2010. Vol. 8 (4). P. 45–49.
2. Barcena R., Moraleda G., Moreno J. et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positi- ve livers // World J. Gastroenterol. 2006. Vol. 12 (13). P. 2070–2074.
3. Cahlin C., Olausson M., and Friman S. Severe clinical course of de novo hepatitis B infection after liver trans- plantation // Transplant Proc. 2001. Vol. 33 (4). P. 2467– 2468.
4. Castells L., Vargas V., Rodriguez F. et al. Clinical impact and efficacy of lamivudine therapy in de novo hepati- tis B infection after liver transplantation // Liver Transpl. 2002. Vol. 8 (10). P. 892–900.
5. Chazouilleres O., Mamish D., Kim M. et al. «Occult» hepatitis B virus as source of infection in liver transplant recipients // Lancet. 1994. Vol. 343 (8890). P. 142–146.
6. Crespo J., Fabrega E., Casafont F. et al. Severe clini- cal course of de novo hepatitis B infection after liver transplantation // Liver Transpl Surg. 1999. Vol. 5 (3). P. 175–183.
7. Demetris A.J., Todo S., Van Thiel D.H. et al. Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations // Am. J. Pathol. 1990. Vol. 137 (3). P. 667–676.
8. Donataccio D., Roggen F., De Reyck C. et al. Use of an- ti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool // Transpl. Int. 2006. Vol. 19 (1). P. 38–43.
9. Douglas D.D., Rakela J., Taswell H. et al. Transmissi- on of hepatitis B virus infection from orthotopic donor livers [abstract] // Hepatology. 1992. Vol. 16 (Suppl). P. 49A.
10. Douglas D.D., Rakela J., Wright T.L. et al. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient // Liver Transpl. Surg. 1997. Vol. 3 (2). P. 105–111.
11. EASL Clinical Practice Guidelines: management of chro- nic hepatitis B // J. Hepatol. 2009. Vol. 50 (2). P. 227–242.
12. Fabia R., Levy M.F., Crippin J. et al. De novo hepatitis B infection after liver transplantation: source of disease, in- cidence, and impact // Liver Transpl. Surg. 1998. Vol. 4 (2). P. 119–127.
13. Jiang L., Jiang L.S., Cheng N.S. et al. Current prophylactic strategies against hepatitis B virus recurrence af- ter liver transplantation // World J. Gastroenterol. 2009. Vol. 15 (20). P. 2489–2499.
14. Jiang L. and Yan L.N. Current therapeutic strategies for recurrent hepatitis B virus infection after liver trans- plantation // World J. Gastroenterol. 2010. Vol. 16 (20). P. 2468–2475.
15. Kim K.K., Kim K.H., Hwang S. et al. Therapeutic effect of adefovir dipivoxil on recurrent or de novo infection of hepatitis B virus after liver transplantation: a preliminary report // Korean J. Gastroenterol. 2005. Vol. 45 (3). P. 174–180.
16. Marusawa H., Uemoto S., Hijikata M. et al. Latent hepatitis B virus infection in healthy individuals with an- tibodies to hepatitis B core antigen // Hepatology. 2000. Vol. 31 (2). P. 488–495.
17. Perrillo R., Rakela J., Dienstag J. et al. Multicenter stu- dy of lamivudine therapy for hepatitis B after liver trans- plantation. Lamivudine Transplant Group // Hepatology. 1999. Vol. 29 (5). P. 1581–1586.
18. Prieto M., Gomez M.D., Berenguer M. et al. De novo he- patitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population // Liver Transpl. 2001. Vol. 7 (1). P. 51–58.
19. Razonable R.R. Cytomegalovirus infection after liver transplantation: current concepts and challenges // World J. Gastroenterol. 2008. Vol. 14 (31). P. 4849– 4860.
20. Roche B., Samuel D., Gigou M. et al. De novo and appa- rent de novo hepatitis B virus infection after liver trans- plantation // J. Hepatol. 1997. Vol. 26 (3). P. 517–526.
21. Roque-Afonso A.M., Feray C., Samuel D. et al. Antibo- dies to hepatitis B surface antigen prevent viral reactiva- tion in recipients of liver grafts from anti-HBC positive donors // Gut. 2002. Vol. 50 (1). P. 95–99.
22. Segovia R., Sanchez-Fueyo A., Rimola A. et al. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation // Liver Transpl. 2001. Vol. 7 (2). P. 106–112.
23. Su W.J., Ho M.C., Ni Y.H. et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection // J. Pediatr. Gastroenterol Nutr. 2009. Vol. 48 (2). P. 203–208.
24. Takemura N., Sugawara Y., Tamura S. et al. Liver trans- plantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience // Dig Dis Sci. 2007. Vol. 52 (10). P. 2472–2477.
25. Toniutto P., Fumo E., Caldato M. et al. Favourable out- come of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation // Transplantation. 2004. Vol. 77 (3). P. 472–473.
26. Uemoto S., Sugiyama K., Marusawa H. et al. Transmis- sion of hepatitis B virus from hepatitis B core antibo- dy-positive donors in living related liver transplants // Transplantation. 1998. Vol. 65 (4). P. 494–499.
27. Umeda M., Marusawa H., Ueda M. et al. Beneficial ef- fects of short-term lamivudine treatment for de novo he- patitis B virus reactivation after liver transplantation // Am. J. Transplant. 2006. Vol. 6 (11). P. 2680–2685.
28. Wachs M.E., Amend W.J., Ascher N.L. et al. The risk of transmission of hepatitis B from HBsAg(–), HBcAb(+), HBIgM(–) organ donors // Transplantation. 1995. Vol. 59 (2). P. 230–234.
29. Yilmaz N., Shiffman M.L., Todd Stravitz R. et al. Prophy- laxis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 ye- ars // Liver Int. 2008. Vol. 28 (1). P. 72–78.
Review
For citations:
Syutkin V.E., Andreytzeva O.I., Salienko A.A., Chugunov A.O., Chzhao A.V. DIFFERENT COURSES OF HBV INFECTION AFTER LIVER TRANSPLANTATION. Russian Journal of Transplantology and Artificial Organs. 2011;13(2):37-45. (In Russ.) https://doi.org/10.15825/1995-1191-2011-2-37-45
Views:
766
Email this article 